Frank J. Dutko

Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound

Susan A. Charman, William N. Charman, Mark Rogge et al. · Pharmaceutical Research · 1992 · 376 citations

Pharmacy, Pharmaceutics, Pharmacology +16

Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

Gregory J. Dore, Frederick L. Altice, Alain H. Litwin et al. · Annals of Internal Medicine · 2016 · 363 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 300 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

The structure of coxsackievirus B3 at 3.5 å resolution

J.K. Muckelbauer, Marcia J. Kremer, Iwona Minor et al. · Structure · 1995 · 280 citations

Life Sciences, Biology, Molecular Biology +12

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hézode, Jan Gerstoft et al. · The Lancet · 2014 · 280 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14